ASH 2015 | Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemia
Elias Jabbour, MD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about a Phase II clinical trial of inotuzumab ozogamicin in elderly acute lymphoblastic leukemia (ALL) patients, presented at the American Society of Hematology (ASH) 2015 Annual Meeting, Orlando, FL. Inotuzumab ozogamicin is an anti-CD22 antibody that contains a toxin attached to it, called calicheamicin. When the antibody binds to the cells, the toxin is internalized, binds to DNA, resulting in cell death. This drug was administered to relapsed/refractory patients, in combination with lower-dose chemotherapy (mini-hyper-CVD). The drug proved to be very effective, with a response rate of 95%, and all patients achieving minimum residual disease (MRD) negativity status. Dr Jabbour also discusses the side-effects observed in this study.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, at Orlando, FL.
